Screening of Investigational Compounds to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)   2

Background
The solicitation is for the Screening of Investigational Compounds to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP). The contract is issued by the Office of Acquisitions, National Institute on Drug Abuse, NINDS Section, CMB Red, National Institutes of Health in Bethesda, MD. The set-aside is specified in Part IV Section L. Offerors must be registered in the System for Award Management (SAM) prior to contract award. The proposal intent response sheet is due by 12:00 PM EST on November 23, 2021.

Work Details
The work includes furnishing all necessary services, qualified personnel, material, equipment, and facilities to perform the Statement of Work. The Contractor shall provide screening of investigational therapeutics to treat, modify or prevent epilepsy as per the attached Statement of Work dated 10/08/2021. The Contractor shall submit technical progress reports monthly, semi-annually, annually (with a requirement for a Draft Annual Report), and a final report upon completion of the contract. Other reports/deliverables include reporting of Financial Conflict of Interest (FCOI) and providing accelerated payment to small business subcontractors.

Period of Performance
The period of performance includes a Base Period of 9 months with an estimated cost and fixed fee to be determined. There are also Option Periods 1-5 each lasting 12 months and a Total Option Period lasting 3 months. Additionally, there are Quantity Options that can be exercised multiple times.

Place of Performance
The place of performance is not explicitly specified in the provided information.